Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
01:32pm, Tuesday, 30'th Aug 2022
Novartis (NVS) strengthens its oncology portfolio with EC approval for its chronic myeloid leukemia drug, Scemblix.
5 High-Yield Dividend Aristocrats To Thrive During This Bear Market
11:00am, Tuesday, 30'th Aug 2022 Seeking Alpha
Stocks might still fall as much as 30% from here if we get a recession in 2023. Read about 5 dividend aristocrats to survive and thrive in this bear market.
Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre
03:31pm, Monday, 29'th Aug 2022 Zacks Investment Research
Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer
11:43am, Monday, 29'th Aug 2022 Zacks Investment Research
Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.
U.S.-China relations just got a whole lot better, boosting the prospects of these three stocks
10:34am, Sunday, 28'th Aug 2022 MarketWatch
Securities regulators in the two countries came to an agreement on audit protocols, lifting an overhang on Chinese stocks.
Novartis Looks Appealing, Based on Strong Drug Pipeline and Planned Sandoz Spinoff
06:25pm, Friday, 26'th Aug 2022
These reports, excerpted and edited by Barron's, were issued recently by investment and research firms. The reports are a sampling of analysts' thinking; they should not be considered the views or rec
Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why
05:35pm, Friday, 26'th Aug 2022 Zacks Investment Research
Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
05:17pm, Friday, 26'th Aug 2022 Zacks Investment Research
Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.
Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates
01:09pm, Friday, 26'th Aug 2022 Zacks Investment Research
Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.
Analysis-Novartis CEO may struggle to rally investors to Sandoz spin-off
01:11am, Friday, 26'th Aug 2022
Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker drug prices and jittery financial markets present one of his biggest challenges
Novartis: Undervalued And Trustworthy
05:30pm, Thursday, 25'th Aug 2022
In the event of a recession, this is a stock that can potentially do better than the market, and so far it has already proven that. Novartis' dividend currently has a dividend yield (FWD) of 3.98%, mu
Novartis (NVS) Plans to Spin Off Generics Business Sandoz
01:49pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.
Sandoz will be a long-term stable business if it can get its cost structure right, Novasecta says
06:28am, Thursday, 25'th Aug 2022
John Rountree, managing partner at pharma consultancy Novasecta, discusses Novartis' decision to spin off generics business Sandoz.
Novartis to spin off, list Sandoz business
05:53am, Thursday, 25'th Aug 2022 MarketWatch
The Swiss pharmaceutical company said Sandoz would be based in Switzerland and listed locally alongside a an American depositary receipt program in the U.S.
Novartis to spin off, list Sandoz business
01:53am, Thursday, 25'th Aug 2022
Novartis AG is planning to spin off its generics-and-biosimilars division Sandoz and list it as a standalone company in Switzerland, a move that will enable Novartis to focus on innovative medicines.
